Subclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib
American Journal of Clinical Pathology · 2026
DOI: 10.1093/ajcp/aqag115 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Clinical Pathology, 2026. Verfasst von Fnu Monika und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. Hauptthemen laut MEDLINE: Receptor, Platelet-Derived Growth Factor beta, Imatinib Mesylate, Myelodysplastic-Myeloproliferative Diseases, Oncogene Proteins, Fusion. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Objectives
Myeloid/lymphoid neoplasms with PDGFRB rearrangements are rare hematologic malignancies with marked clinicopathologic and genetic heterogeneity. AGGF1 is an exceptionally rare PDGFRB fusion partner previously reported only in pediatric lymphoblastic leukemia. Here, we describe the first AGGF1::PDGFRB rearrangement in a myeloid neoplasm and characterize its clonal evolution.
Methods
A man older than 80 years of age with progressive leukocytosis, anemia, and thrombocytopenia underwent bone marrow examination, conventional karyotyping, next-generation DNA sequencing, and RNA sequencing.
Results
The bone marrow showed features of a myelodysplastic/myeloproliferative neoplasm with neutrophilia. Molecular studies identified clonally dominant pathogenic DNMT3A, RUNX1, SF3B1, and WT1 mutations and KMT2A partial tandem duplication. RNA sequencing detected a subclonal AGGF1::PDGFRB fusion, supported by inv(5)(q13q33) in 6 of 20 metaphases. Hydroxyurea and imatinib produced a marked reduction in leukocyte count within 1 month. Two months later, however, the disease progressed to acute myeloid leukemia with acquisition of FLT3 internal tandem duplication, while AGGF1::PDGFRB was no longer detectable.
Conclusions
This case expands the spectrum of PDGFRB-rearranged myeloid neoplasms and demonstrates that a potentially targetable tyrosine kinase rearrangement may arise as a subclonal rather than a founding event. Defining clonal architecture and temporal evolution is therefore important for accurate disease classification, therapy selection, and interpretation of treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
- Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
- Leukemia & Myeloid Disorders Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States.
- Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
ORCID-Profile: Mingfei Yan
Zitieren
APA
Monika, F., Shao, H., Jain, A. G., Tackett, M., Kuykendall, A. T., Sallman, D. A., & Yan, M. (2026). Subclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqag115
Vancouver
Monika F, Shao H, Jain AG, Tackett M, Kuykendall AT, Sallman DA, et al. Subclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib. American Journal of Clinical Pathology. 2026. doi:10.1093/ajcp/aqag115
BibTeX
@article{Monika2026,
author = {Monika, Fnu and Shao, Haipeng and Jain, Akriti G and Tackett, Michelle and Kuykendall, Andrew T and Sallman, David A and Yan, Mingfei},
title = {Subclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib},
journal = {American Journal of Clinical Pathology},
year = {2026},
doi = {10.1093/ajcp/aqag115}
}
EUVIMED